OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
March 21, 2023
Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.
BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.
March 17, 2023
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.
March 03, 2023
EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.
March 02, 2023
Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.
March 01, 2023
AstraZeneca has entered into a global exclusive license agreement with KYM Biosciences for CMG901, which is being investigated as a gastric cancer treatment.
February 24, 2023
Moderna will leverage Life Edit’s suite of gene editing technologies to advance development of in vivo gene editing therapies.